Provided by Tiger Fintech (Singapore) Pte. Ltd.

Praxis Precision Medicines, Inc.

40.75
-6.1000-13.02%
Volume:1.51M
Turnover:61.35M
Market Cap:857.77M
PE:-3.30
High:43.15
Open:41.94
Low:37.19
Close:46.85
52wk High:91.83
52wk Low:26.70
Shares:21.05M
Float Shares:16.04M
Volume Ratio:4.42
T/O Rate:9.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.3300
EPS(LYR):-10.2095
ROE:-60.98%
ROA:-37.98%
PB:2.12
PE(LYR):-3.99

Loading ...

BRIEF-Praxis Precision Medicines Terminates 2024 Sales Agreement With Jefferies - SEC Filing

Reuters
·
Sep 06

Praxis Precision Medicines Inc. Files Prospectus Supplement for New Common Stock Offerings Under 2025 Sales Agreement

Reuters
·
Sep 06

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 04

U.S. RESEARCH ROUNDUP-BOK Financial, Sable Offshore, Zscaler

Reuters
·
Sep 03

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

GlobeNewswire
·
Aug 29

U.S. RESEARCH ROUNDUP-Home Depot, Upstart, Vita Coco

Reuters
·
Aug 20

Praxis Precision Medicines Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $61 VS $105

THOMSON REUTERS
·
Aug 20

Praxis Precision Medicines Inc. Files Initial Ownership Statement; Adage Capital Management Named as Beneficial Owner

Reuters
·
Aug 20

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Aug 07

Wedbush Raises Price Target on Praxis Precision Medicines to $33 From $28, Keeps Underperform Rating

MT Newswires Live
·
Aug 05

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

GlobeNewswire
·
Aug 05

Stock Track | Praxis Precision Medicines Plummets 10.18% on Mixed Q2 Results Despite Positive Drug Trial Data

Stock Track
·
Aug 04

Praxis Precision Medicines Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 04

Praxis Precision Medicines Unveils Corporate Presentation Highlighting Innovations in CNS Disorder Treatments

Reuters
·
Aug 04

Stock Track | Praxis Precision Medicines Plunges 5.53% Pre-market on Mixed Q2 Results Despite Positive Drug Trial Data

Stock Track
·
Aug 04

Praxis Precision Medicine Q2 2025 EPS $(3.31) Misses $(3.25) Estimate, Cash And Investments Of Approximately $447M Maintains Runway Into 2028

Benzinga
·
Aug 04

BRIEF-Praxis Precision Q2 EPS USD -3.31 Vs. IBES Estimate USD -3.3

Reuters
·
Aug 04

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 04

Praxis Precision Q2 EPS USD -3.31 VS. Ibes Estimate USD -3.3

THOMSON REUTERS
·
Aug 04

Praxis Precision Q2 Operating Income USD -76.067 Million VS. Ibes Estimate USD -73.1 Million

THOMSON REUTERS
·
Aug 04